Novel oral anticoagulant prescriptions soar, but at a high cost

Warfarin, the longtime standard treatment for atrial fibrillation, is facing competition from new options in the anticoagulant drug marketplace including dabigatran, rivaroxaban, and apixaban. A new study documents the rapid adoption of these novel oral anticoagulants (NOACs) into clinical practice. By mid-2013 NOACs accounted for 62% of all new anticoagulant prescriptions yet this represents 98% of total anticoagulant-related drug costs. Findings are published in The American Journal of Medicine.

Atrial fibrillation (AF) is a serious heart arrhythmia that can increase a patient's risk for stroke and blood clots. For many years has been the only anticoagulant available to patients with AF. Relatively inexpensive, warfarin was effective, but not well tolerated by patients because of necessary routine monitoring, dietary restrictions, and increased bleeding risks, especially in older patients. Recently, a group of NOACs has been approved by the FDA, which includes (Pradaxa), rivaroxaban (Xarelto), and apixaban (Eliquis). These new medications require no monitoring and have been shown to work just as well or better than warfarin in randomized trials.

Commenting on the study, Joseph S. Alpert, MD, Professor of Medicine, University of Arizona College of Medicine, Tucson, writes that "Given the much simpler clinical protocol associated with a NOAC, it is not surprising that the NOACs accounted for 62% of new anticoagulant prescriptions during that time period. Ease of use undoubtedly accounted for this rapid switch from warfarin to a NOAC."

In order to better understand NOAC adoption and prescription trend, researchers analyzed medical and prescription claims data from a large American medical insurance company. They identified patients with AF who were prescribed an oral anticoagulant from 2010-2013 and found that during that time period, NOACs accounted for 62% of new prescriptions, meaning that physicians are rapidly adopting NOACs as an acceptable alternative to warfarin, particularly among patients with lower CHADS2 (Congestive heart failure, Hypertension, Age >75 years, Diabetes mellitus, Stroke) scores and HAS-BLED (Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile international normalized ratio, Elderly [Age >65 years], Drugs/alcohol concomitantly) scores.

While being prescribed with increasing frequency, the study determined that NOACs were less likely to be given to women and people in lower income areas. Researchers also identified that NOACs were most regularly prescribed to patients with lower CHADS2 and HAS-BLED scores, while warfarin was still being used for those with higher scores. Researchers note that this is significant because in the clinical trials conducted to approve NOACs, most patients had CHADS2 scores in the higher ranges.

"The greatest absolute benefit from novel anticoagulants has been shown in clinical trials to be among patients at highest baseline risk for stroke or systemic embolization, which is at odds with our observation of selection of seemingly lower-risk patients for these drugs," observes lead investigator Niteesh K. Choudhry, MD, PhD, Associate Professor of Medicine at Harvard Medical School and an Associate Physician in the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women's Hospital, Boston. "Such a finding may reflect provider conservatism for new drug adoption, particularly given longitudinal experience with warfarin."

But these new drugs come at a price and high health care cost consequences. The data revealed that NOACs represented 98% of the total dollars spent on anticoagulants from 2010 to 2013. Specifically, over the first six months, the average combined patient and insurer cost associated with starting a NOAC was $900 greater than the costs of starting warfarin, meaning the burden for both insurance and patients is much higher with NOACs.

"The observed patterns of anticoagulant initiation among patients with additionally have important economic implications for patients, payers, and the health care system," notes Dr. Choudhry. "Average patient out-of-pocket and insurance spending was more than 5-fold and 15-fold higher, respectively, for novel anticoagulants as compared with warfarin. A 6-month difference in total costs of $900 in our cohort translates into billions of dollars at a national level."

While the rapid adoption of NOACs is good news for patients and doctors who would like more AF medication choices, this study indicates that more information may be needed to fully understand the implications of rising NOAC .

"These findings point to the need to conduct ongoing surveillance of the adoption of new agents into , as well as the need for robust, real-world comparative-effectiveness analyses of these medications, to enable and providers to make informed decisions about their relative benefit, safety, and cost-effectiveness," concludes Dr. Choudhry.

Dr. Alpert expects that the utilization of the NOACs will increase over time, cost will gradually become less of an issue, particularly once they become generic, and new protocols will be devised to minimize, but never eliminate, bleeding risk.

Explore further

ESC guide on new oral anticoagulant drugs

More information: "Patterns of Initiation of Oral Anticoagulants in Patients with Atrial Fibrillation—Quality and Cost Implications," by Nihar R. Desai, MD, MPH, Alexis A. Krumme, MS, Sebastian Schneeweiss, MD, ScD, William H. Shrank, MD, MSHS, Gregory Brill, MS, Edmund J. Pezalla, MD, MPH, Claire M. Spettell, PhD, Troyen A. Brennan, MD, JD, MPH, Olga S. Matlin, PhD, Jerry Avorn, MD, Niteesh K. Choudhry, MD, PhD (

"The NOACs (Novel Oral Anticoagulants) have landed!" by Joseph S. Alpert, MD (

Both are published online in advance of The American Journal of Medicine, Volume 127/Issue 11 (November 2014)

Journal information: American Journal of Medicine

Provided by Elsevier
Citation: Novel oral anticoagulant prescriptions soar, but at a high cost (2014, August 19) retrieved 30 July 2021 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors

User comments